Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. - Wikidata - wikimedia - TriplyDB

Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.

Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.

http://www.wikidata.org/entity/Q34787780

about

Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View A Systems Biology Overview on Human Diabetic Nephropathy: From Genetic Susceptibility to Post-Transcriptional and Post-Translational Modifications Nonimmunologic targets of immunosuppressive agents in podocytes Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade Podocyte pathology and nephropathy - sphingolipids in glomerular diseases Crystal Structure of the Acid Sphingomyelinase-Like Phosphodiesterase SMPDL3B Provides Insights into Determinants of Substrate Specificity The Lipid-Modifying Enzyme SMPDL3B Negatively Regulates Innate Immunity Identification and biochemical characterization of an acid sphingomyelinase-like protein from the bacterial plant pathogen Ralstonia solanacearum that hydrolyzes ATP to AMP but not sphingomyelin to ceramide Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.Exercise-mimetic AICAR transiently benefits brain function.Soluble Urokinase Receptor and Chronic Kidney Disease.Targeted Lipidomic and Transcriptomic Analysis Identifies Dysregulated Renal Ceramide Metabolism in a Mouse Model of Diabetic Kidney Disease Nephrin Contributes to Insulin Secretion and Affects Mammalian Target of Rapamycin Signaling Independently of Insulin Receptor Systemic and renal lipids in kidney disease development and progression.Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.Diabetes mellitus in the transplanted kidney.Podocytes … What's Under Yours? (Podocytes and Foot Processes and How They Change in Nephropathy).Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Focal segmental glomerular sclerosis: do not overlook the role of immune response.Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease.Podocyte-actin dynamics in health and disease.Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor.Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes.Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.Translational Aspects of Sphingolipid Metabolism in Renal Disorders.Investigational drugs in development for focal segmental glomerulosclerosis.Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease.

P2860

Q26738374-1CFD87AC-03BB-42F9-98CE-2F02CDE62B0A Q26769678-BF304EE4-4FFA-4672-BC9A-7786A52589A4 Q26781358-CF658E83-8249-4547-9C16-49CE0CCDE7F9 Q26799443-72F22EA6-70F1-4402-82DC-7523FC667D39 Q26852463-19931199-0F3C-4729-BEB6-B890B3A867A9 Q27728145-0EE3CB6C-3C33-4B7C-A95D-26E6D4C40D1C Q28115270-90D4E056-B814-4D53-B4B7-D08E8F5F6199 Q28542500-605AFDBF-6260-4BBF-96E2-A1E355FB4FFF Q33741426-2AE0E437-D651-4B35-997E-467D354F2EBF Q35779133-C3EC95A1-7950-472F-B244-40BF22BAA0E3 Q36210852-AEB0DBA6-DBB4-4188-8BD2-5AFBBBA6733B Q36429637-EA2EB50A-6CAD-4659-AA7E-4B856C6F7273 Q36462205-72F4D5DA-CCB7-41AF-B9D0-D054EB9D69ED Q36746094-232C8BDC-A719-4055-9F41-6798E1F885D4 Q37148885-32D0FFC4-6D08-4F9E-AFE1-B492F76CC097 Q37217446-7433FC32-76C3-4362-9589-90CF88213A60 Q37587674-DFA09796-2597-4806-B503-83D67530A2C0 Q37716096-4D52E3CC-B4BE-4198-BB4D-94234E0440F9 Q38249183-E2CC8E60-F228-4B6F-AFAE-1CE35BFE991D Q38371649-6166C5F1-1F8F-47AF-A7E7-2723AAA49FF7 Q38679589-7D235520-AFBF-497B-9758-55D4A43A300D Q38742004-7906B339-3126-46A4-8BEE-4B86CCB1BAEE Q38770231-884F430A-2CCE-44E1-ABB3-68BE401E2971 Q38940494-B3D80E96-32A3-4302-9398-AEB8AC2CE3FA Q41688065-61A51941-50D2-420E-8583-0FE223C22C3F Q42501631-671317C1-287A-41F7-9303-45DFFC4BE4B2 Q44256854-351225FF-6CEC-4C5D-9E32-FC5445B3EB38 Q47854753-B607C62F-E219-4C01-AA09-4570AD6EB42E Q49399657-9343D648-57B7-4476-8F3D-004249386734 Q51840896-206552A2-0AFC-4020-A03F-8CA2F87D14F3 Q55251661-5E3B615E-C147-4EAC-9F3E-BE52AAAAFAF2

P2860

Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.

http://www.wikidata.org/entity/Q34787780

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Sphingomyelinase-like phosphod ...... notypes in glomerular disease.

@ast

Sphingomyelinase-like phosphod ...... notypes in glomerular disease.

@en

Sphingomyelinase-like phosphod ...... notypes in glomerular disease.

@nl

type

label

Sphingomyelinase-like phosphod ...... notypes in glomerular disease.

@ast

Sphingomyelinase-like phosphod ...... notypes in glomerular disease.

@en

Sphingomyelinase-like phosphod ...... notypes in glomerular disease.

@nl

prefLabel

Sphingomyelinase-like phosphod ...... notypes in glomerular disease.

@ast

Sphingomyelinase-like phosphod ...... notypes in glomerular disease.

@en

Sphingomyelinase-like phosphod ...... notypes in glomerular disease.

@nl

P1433

Q34787780-C01FF71D-78A8-468D-8EFC-766C2E1F255A

P1476

Q34787780-1ABEF88C-36EE-40D4-8086-F551ABBA3554

P2093

Q34787780-14B5E86B-C139-4232-8EB8-7903745A57A5

Q34787780-1BC93BE8-32CD-44BC-AACD-F3CAA33EEF6A

Q34787780-28773C44-CA15-47AC-BC14-2886835CE2FB

Q34787780-3894CDCF-41F3-4137-9E01-0A3585A304B8

Q34787780-590DD644-1320-43CF-B8E9-7272EC882352

Q34787780-59F9AC16-9A91-4919-B87B-0F21AF2FAFE6

Q34787780-68F43863-A464-41D3-9391-DA0789EE5FF2

Q34787780-712F19DC-C3DC-4C38-B052-BE494B57856E

Q34787780-A0C24060-A706-493D-87DB-6993BC7604EB

Q34787780-ADC82FD9-65CC-457B-85A5-60941E62F2FE

P2860

Q34787780-2501C3E5-900B-4725-A9EC-53D650382BF1

Q34787780-2E78D4A6-31C2-4ADA-854C-052DE3CF6E1E

Q34787780-404CC797-EF2B-4388-8560-DBBA406D1709

Q34787780-45E3709F-CA58-412C-A634-38C2366723B5

Q34787780-5272F111-9F40-4CE3-A97F-EF8AD76980AC

Q34787780-55C9A9E8-11C3-4F2A-B095-6E0FA127C80F

Q34787780-575A35CB-8A7F-4ACD-9C8C-3706CF2915D0

Q34787780-5A2FDE0B-9925-4332-8D56-750F18D8021B

Q34787780-6115CEFE-E76E-469C-A256-FF4A673FABEE

Q34787780-76999854-E8EB-4B2D-97AB-172B657D0C31

P304

Q34787780-DEAB0F13-8FC0-4EAC-9E6B-083E41DD2F24

P31

Q34787780-A19D8842-A68A-44D9-BB8F-CF3C41F2F9C1

P356

Q34787780-B4529563-6FCB-4331-8AB9-B59A19895C0E

P433

Q34787780-E4F496D3-0A88-405E-A16B-3CCFA482767E

P478

Q34787780-94647584-142C-42AE-AF28-68FE02FB9A28

P50

Q34787780-19B5C256-5977-4088-8EAC-FB601ED789F3

Q34787780-FB0C759C-90C2-44EA-B2A5-A0CE38496756

P577

Q34787780-AB79E69A-DC12-454E-B78B-6F199626035E

P5875

Q34787780-7E2FD722-E126-4CA8-8C3B-33BE963E52CE

P698

Q34787780-CBFEDDC2-04A7-4FE7-8338-5CFB24FF321E

P932

Q34787780-406BB8A2-F866-4A75-8495-00EDF31E6800

P356

P1433

Journal of the American Society of Nephrology

P1476

Sphingomyelinase-like phosphod ...... notypes in glomerular disease.

@en

P2093

Alessia Fornoni

http://www.w3.org/2001/XMLSchema#string

Alla Mitrofanova

http://www.w3.org/2001/XMLSchema#string

Changli Wei

http://www.w3.org/2001/XMLSchema#string

Christian Faul

http://www.w3.org/2001/XMLSchema#string

Christopher E Pedigo

http://www.w3.org/2001/XMLSchema#string

Farah Leclercq

http://www.w3.org/2001/XMLSchema#string

George William Burke

http://www.w3.org/2001/XMLSchema#string

Jing Li

http://www.w3.org/2001/XMLSchema#string

Jochen Reiser

http://www.w3.org/2001/XMLSchema#string

Johanna Guzman

http://www.w3.org/2001/XMLSchema#string

P2860

Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner

Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review

Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling

RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.

Apoptotic effect of sphingosine 1-phosphate and increased sphingosine 1-phosphate hydrolysis on mesangial cells cultured at low cell density.

Gene expression profiling analysis in nephrology: towards molecular definition of renal disease.

uPAR: a versatile signalling orchestrator.

Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.

Towards a definition of glomerulomegaly: clinical-pathological and methodological considerations

P304

133-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2013111213

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Per-Henrik Groop

P577

2014-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263218393

http://www.w3.org/2001/XMLSchema#string

P698

24925721

http://www.w3.org/2001/XMLSchema#string

P932

4279736

http://www.w3.org/2001/XMLSchema#string